drugset / Trial / NCT03090269
Methylphenidate for Cocaine Dependence
NaSingle-groupOpen-labelTreatment
Summary
This phase II pilot study aims at evaluating the benefits and the risks of methylphenidate (Concerta®) for the treatment of cocaine/crack dependence in terms of cocaine/crack use reduction and adverse events.
Timeline
- Start
- 2018-06-01
- Primary completion
- 2018-12-31
- Completion
- 2019-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Methylphenidate | Small molecule | 108 mg | Oral |